The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1‐84): A retrospective cohort study
Main finding · Incident CKDResult — go to the resultHazard ratio 0.47 95% CI 0.25–0.87Authors' conclusion
Patients with chronic hypoparathyroidism treated with rhPTH(1-84) in long-term clinical trials had a significantly lower risk of developing CKD compared with patients in a historical control cohort not treated with rhPTH(1-84).
Study context
- Population
- Adults with chronic hypoparathyroidism
- Participants
- 118 vs 497
- Exposure
- rhPTH vs no rhPTH
- rhPTH(1-84)n = 118
- Controlsn = 497reference
- Outcome
- Incident chronic kidney disease (CKD) (≥2 estimated glomerular filtration rate (eGFR) measurements <60 ml/min/1.73 m² ≥3 months apart) and sustained eGFR decline ≥30% from baseline
- Follow-up
- Up to 5 years
Methodological detailshistorical control cohort
- Historical control cohort
Main finding
Incident CKD
Hazard ratio
0.47
95% CI 0.25–0.87
rhPTH(1-84)vs Controls
HR 0.47 (95% CI 0.25–0.87)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Sustained eGFR decline ≥30% from baseline · up to 5 yearsrhPTH(1-84)vs ControlsAdjusted; 65% lower risk | 0.35 (0.13–0.89) | |
| 0.10.31310Hazard ratio (log scale) |
| Outcome | P value |
|---|---|
| Sustained eGFR decline ≥30% from baseline · up to 5 yearsrhPTH(1-84) vs Controls · lower risk with rhPTH(1-84) | log-rank p < .001 |
Original publication
The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1‐84): A retrospective cohort study. Clin Endocrinol (Oxf). Published 28 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →